The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1405
Antiviral Drugs for Influenza 2012-2013
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Antiviral drugs can be used as an adjunct to vaccination1 for prophylaxis and treatment of influenza. In recent years, the susceptibility of circulating influenza virus strains has evolved rapidly and treatment recommendations have changed during the influenza season. Frequently updated information on antiviral resistance is available at www.cdc.gov/flu/professionals/antivirals.

THE DRUGS — The neuraminidase inhibitors oseltamivir (Tamiflu), which is taken orally, and zanamivir (Relenza), which is inhaled, have generally been about 70-90% effective for chemoprophylaxis after exposure to susceptible strains of seasonal influenza A or B.2

Treatment with a neuraminidase inhibitor started within 48 hours after the onset of illness in patients infected with a susceptible strain of influenza virus can decrease the duration ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Antiviral Drugs for Influenza 2012-2013
Article code: 1405a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian